- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 09.04. | From ADCs to radiopharma: How AstraZeneca is trying to 'redefine oncology care' | ||
| 09.04. | Judge permanently blocks NIH grant caps, prompting HHS appeal | ||
| 09.04. | Vincerx's final merger attempt collapses, leaving ADC biotech to wind down | ||
| 08.04. | HHS cuts contract spend by 35%, with 334 pacts already terminated | ||
| 08.04. | Third Rock-backed Merida launches with $121M series A to fund autoimmune pipeline | ||
| 08.04. | J&J links FcRn blocker to sustained benefits as FDA ruling on potential blockbuster nears | ||
| 08.04. | Rallybio abandons lead program after phase 2 data in rare maternal disorder disappoint | ||
| 08.04. | KalVista, awaiting FDA call on HAE drug, sells Japanese rights to Kaken in $22M deal | ||
| 08.04. | Congressional commission urges action to maintain US biotech advantage over China | ||
| 07.04. | 'A slow-moving catastrophe': FDA cuts are like firing all hospital staff except doctors, Janet Woodcock says | ||
| 07.04. | Nordic Capital steps away from potential PureTech Health buyout | ||
| 07.04. | Lexeo locks in pivotal trial plan as clinical data pump up prospects of cardiac gene therapy | ||
| 07.04. | Backing from BioNTech powers ADC specialist DualityBio toward $200M Hong Kong IPO | ||
| 07.04. | UK's Epsilogen acquires fellow immunoglobin biotech TigaTx to boost cancer antibody options | ||
| 07.04. | GSK pens $2.5B pact for ABL Bio's tech to help antibodies bypass blood-brain barrier | ||
| 04.04. | Trump administration faces mounting litigation as 16 states sue over NIH grant cuts | ||
| 04.04. | Relay Therapeutics starts third layoff wave in 1 year, shedding 70 staffers | ||
| 04.04. | F-star charts new path, splitting from invoX after 2023's $161M acquisition | ||
| 04.04. | Servier severing forces OPM to make 'drastic choices' to adapt as it cuts staff, executive wages | ||
| 04.04. | Apollomics tags out of TYG oncology pact to cut costs, extend runway into 2026 | ||
| 03.04. | Cell therapy biotech Neurona nabs $102M to push epilepsy candidate into phase 3 | ||
| 03.04. | Roche shows most Alzheimer's patients below amyloid threshold after 28 weeks | ||
| 03.04. | Aldeyra's dry eye drug suffers second FDA rejection, but imminent data spur hope of fast recovery | ||
| 03.04. | BeiGene abandons ociperlimab over poor phase 3 prospects in latest blow to TIGITs | ||
| 03.04. | Boehringer commits $31M to ADC R&D via new Swiss facility for NBE Therapeutics |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
